Quality of Life in Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine and Nab-paclitaxel
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nab-paclitaxel
Related studies linked through entity extraction aliases.
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- TERMINATED
- Phase
- PHASE3
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Treatment With Nab-paclitaxel in Cutaneous SCC
- Status
- TERMINATED
- Phase
- PHASE2
Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
- Status
- COMPLETED
- Phase
- NA
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Nab-Paclitaxel to Paclitaxel in Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.
- Status
- COMPLETED
- Phase
- PHASE2
Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection
- Status
- COMPLETED
- Phase
- PHASE2
Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
- Status
- COMPLETED
- Phase
- PHASE3
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE1
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1